JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch

It’s day three of the 40th annual J.P. Morgan Healthcare Conference. We’ve already heard about Amgen’s biosimilar ambitions and Gilead Sciences’ long-term HIV strategy, but there’s still plenty of action to come. Be sure to check in throughout the day to get the skinny on all the biggest happenings from the virtual conference.

For instance, today we're hearing about Eli Lilly's plans for its forthcoming diabetes med tirzepatide, Ipsen's dealmaking plans and Bausch Health's progress toward its three-way split.